Extra: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
(33 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :CD138 is a marker used to identify normal or malignant plasma cells with a high level of specificity, but does not discriminate normal from abnormal plasma cells and in some cases expression in myeloma may be low compared with normal plasma cells so sensitivity can be an issue. Abberancy of expression is low, but expression may be seen in lymphoplamacytic or marginal zone lymphomas (only on those cells that have plasma cell differentiation) | ||
Line 11: | Line 11: | ||
: | <span style="color:navy">'''Normal expression and function'''</span> | ||
CD138 is a membrane protein that supports cell adhesion or binds cytokines and chemokines. In the hematopoietic system expression of CD138 is acquired by B lymphocytes as they develop into plasma cells. | |||
<span style="color:navy">'''Diagnostic role'''</span> | |||
*Most often CD138 used in conjunction with CD38 to identify plasma cells in the diagnosis or monitoring of myeloma | |||
*There is very little aberrant expression, but neoplastic plasma cells may in some cases have weak, variable, or occasionally undetectable expression | |||
*Expression is also seen cells that have plasmacytic differentiation in lymphoplasmacytoid lymphoma or marginal zone lymphoma | |||
----- | |||
<span style="color:navy">'''Other useful information'''</span> | |||
Outside of haematopoiesis CD138 is expressed by squamous epithelium. | |||
---- | |||
<span style="color:navy">'''''SUMMARY TABLES'''''</span> | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 87.5%; height 20px;" | |||
|- | |||
!colspan="7"|<span style="font-size:100%">'''Expression: primitive cell types''' ''Click (i) on table for additional information'' </span></font> | |||
|- | |||
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)|i]]) || H.gones ('''[[Haematogones|i]]''') | |||
|- | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|- | |||
|} | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;" | |||
|- | |||
!colspan="8"|'''Expression: mature B cell neoplasms''' | |||
|- | |||
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | |||
|- | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #66e0ff; color:black"|5-20% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #66e0ff; color:black"|5-20% | |||
|style="width: 14.25%; background: #006699; color:white"|40-80% | |||
|style="width: 12.5%; background: #004466; color:white"|80-100% | |||
|- | |||
|} | |||
<span style="font-size:90%">'''Notes:''' expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL</span> | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;" | |||
|- | |||
!colspan="7"|'''Expression: mature T cell neoplasms''' | |||
|- | |||
! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL | |||
|- | |||
|style= "width: 20%; background: #FFE4E1; color:black"|limited | |||
|style="width: 20%; background: #FFE4E1; color:black"|limited | |||
|style="width: 20%; background: #FFE4E1; color:black"|limited | |||
|style= "width: 20%; background: #FFE4E1; color:black"|limited | |||
|style="width: 20%; background: #FFE4E1; color:black"|limited | |||
|- | |||
|} | |||
<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders</span> | |||
---- |
Latest revision as of 20:53, 13 June 2023
- Summary
- CD138 is a marker used to identify normal or malignant plasma cells with a high level of specificity, but does not discriminate normal from abnormal plasma cells and in some cases expression in myeloma may be low compared with normal plasma cells so sensitivity can be an issue. Abberancy of expression is low, but expression may be seen in lymphoplamacytic or marginal zone lymphomas (only on those cells that have plasma cell differentiation)
Normal expression and function
CD138 is a membrane protein that supports cell adhesion or binds cytokines and chemokines. In the hematopoietic system expression of CD138 is acquired by B lymphocytes as they develop into plasma cells.
Diagnostic role
- Most often CD138 used in conjunction with CD38 to identify plasma cells in the diagnosis or monitoring of myeloma
- There is very little aberrant expression, but neoplastic plasma cells may in some cases have weak, variable, or occasionally undetectable expression
- Expression is also seen cells that have plasmacytic differentiation in lymphoplasmacytoid lymphoma or marginal zone lymphoma
Other useful information
Outside of haematopoiesis CD138 is expressed by squamous epithelium.
SUMMARY TABLES
Expression: primitive cell types Click (i) on table for additional information | ||||||
---|---|---|---|---|---|---|
AML | B ALL | Burkitt | T ALL | ETP ALL (i) | MPAL (i) | H.gones (i) |
<5% | <5% | <5% | <5% | <5% | <5% | <5% |
Expression: mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
<5% | <5% | <5% | 5-20% | <5% | 5-20% | 40-80% | 80-100% |
Notes: expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL
Expression: mature T cell neoplasms | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL Sezary | T-PLL | T-LGL | NK-LGL | ||
limited | limited | limited | limited | limited |
Notes: limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders